💥Join UPSC 2027,2028 Mentorship (August Batch) + XFactor Notes & Microthemes PDF
Talk to Mentor

Civilsdaily

Login

Subject: Biotech and Medical Sciences

  • Don’t ignore the threat of antimicrobial resistance

    Central idea

    The article highlights challenges in combating Antimicrobial Resistance (AMR), citing an implementation gap in National Action Plans. It calls for global collaboration, emphasizing regional plans, international funding, and patent reforms. Key data underscores the urgency, especially in G20 nations, where coordinated efforts are crucial to address the significant toll of AMR-related deaths.

    What is antimicrobial resistance?

    Antimicrobial Resistance (AMR) is when germs like bacteria and viruses become strong and don’t respond to medicines, making the medicines not work well. This is a big problem because it makes it hard to treat infections, and the resistant germs can spread. We need to work together to make sure our medicines keep working against these germs.

    Key Highlights:

    • Delhi Declaration Commitments: The G20, including India, pledged to strengthen global health systems, implement the One Health approach, and prioritize tackling Antimicrobial Resistance (AMR) through research and development (R&D).
    • AMR’s Global Impact: A Lancet report revealed that AMR caused 4.95 million deaths globally, comparable to HIV and malaria. Sub-Saharan Africa and South Asia faced the highest death rates.
    • G20’s Significance: G20 countries, housing over 60% of the world’s population, address AMR’s threat. Africa, now part of the coalition, adds complexity due to lower investments in healthcare infrastructure.

    Challenges and Concerns:

    • Implementation Gap: Despite comprehensive National Action Plans (NAPs), the efficacy varies, hindering the global effort against AMR.
    • Global Disparities: Low and middle-income countries, especially in Africa, face challenges in dealing with AMR due to limited healthcare infrastructure investments.

    Analysis:

    • Global Collaboration Needed: The success of the Delhi Declaration requires global and local efforts. Prioritizing regional AMR action plans, international funding for R&D, and patent reforms are crucial.
    • Local-Level Action: Effective implementation of NAPs, strengthening surveillance, and promoting responsible antibiotic use are imperative. India’s existing initiatives like Free Diagnostic Services and Kayakalp can play a pivotal role.

    Key Data and Facts:

    • AMR’s Toll: Lancet’s 2021 report associates 1.27 million deaths directly with bacterial AMR, with Sub-Saharan Africa and South Asia facing the highest death rates.
    • G20’s Population Impact: G20 countries house over 60% of the world’s population, making their commitment crucial in tackling AMR globally.

    Way Forward:

    • Regional Action Plans: G20 countries should collaborate with developing nations to create regional AMR action plans, enhancing global coordination.
    • International Funding Mechanism: Advocating for an international funding mechanism focusing on AMR R&D is vital to address global disparities.
    • Patent Reforms: G20 nations should consider promoting patent reforms to foster innovation and ensure affordability in new antibiotics, learning from models like the Medicines Patent Pool.
    • Local-Level Prioritization: Countries need to prioritize NAP implementation, expand monitoring networks, and promote responsible behavior to combat AMR effectively.

  • NexCAR19: India’s own CAR-T Cell Therapy

    car-t cart cell therapy

    Central Idea

    • India has achieved a significant milestone in the field of cancer treatment with the approval of NexCAR19, its first indigenous CAR-T Cell Therapy, by the Central Drugs Standard Control Organisation (CDSCO).
    • Developed by ImmunoACT, an incubated company of IIT Bombay, NexCAR19 is set to transform cancer treatment in India and make it more affordable.

    What is CAR-T Cell Therapy?

    • Revolutionary Approach: CAR-T cell therapy involves modifying T-cells, a type of white blood cell, into potent cancer-fighting cells.
    • Targeting Cancer: These genetically enhanced cells are reintroduced into the patient’s body, where they identify and eliminate cancer cells, particularly effective against blood cancers like leukemia and lymphomas.
    • Game-Changer: Unlike chemotherapy or immunotherapy, CAR-T therapy offers the potential for a cure and lifelong benefits, making it a transformative treatment option.

    NexCAR19: India’s Indigenously Developed CAR-T Therapy

    • NexCAR19 is designed to target cancer cells carrying the CD19 protein, a marker on cancer cells, enhancing precision in treatment.
    • India joins a select group of nations with its own CAR-T and gene therapy platform, reducing dependence on imports.
    • Initially approved for patients aged 15 and above with B-cell lymphomas who did not respond to standard treatments, leading to relapse or recurrence.

    Effectiveness and Unique Features

    • Approximately 70% of patients respond to NexCAR19 treatment, with some achieving complete remission.
    • Lab and animal studies indicate lower drug-related toxicities, including reduced neurotoxicity and Cytokine Release Syndrome (CRS).
    • Trials for paediatric patients are underway at Tata Memorial Hospital, ensuring broader applicability.

    Availability and Affordability

    • ImmunoACT is in the process of securing licenses and partnering with hospitals, including Tata Memorial, Nanavati, Fortis, and Jaslok, across multiple cities.
    • CAR-T therapy is expected to be available in a matter of weeks to a few months, pending final government approvals.
    • Initially priced at Rs 30-40 lakh, ImmunoACT aims to eventually reduce the cost to Rs 10-20 lakh, making the therapy more accessible.
    • Approval by regulatory agencies like CDSCO should lead to insurance coverage, but the extent may vary, and discussions with insurers and the government are ongoing.

  • Haemoglobin isn’t used only in Blood: Scientists

    Haemoglobin

    Central Idea

    • A groundbreaking study published in Nature has unveiled an unexpected revelation: haemoglobin is not exclusive to RBCs.
    • Scientists from China have discovered that chondrocytes, the cells responsible for cartilage production, also produce haemoglobin, which appears vital for their survival.
    • For decades, textbooks have taught that haemoglobin resides solely in red blood cells (RBCs), responsible for making blood red and transporting oxygen.
    Cartilage: A tough, flexible connective tissue found throughout the human body, providing structural support and reducing friction between bones.

    About Haemoglobin

    Fact Description
    Definition A protein found in red blood cells that transports oxygen from the lungs to tissues and organs.
    Molecular Structure Composed of four subunits: two alpha-globin chains and two beta-globin chains.
    Iron-Binding Each subunit contains an iron atom that binds to oxygen, forming oxy-hemoglobin.
    Oxygen Transport Carries oxygen from the lungs to tissues and releases oxygen for cellular respiration.
    Color Gives red blood cells their red color when oxygenated and appears bluish when deoxygenated.
    Carbon Dioxide Transport Aids in transporting carbon dioxide and hydrogen ions from tissues back to the lungs for exhalation.
    Hemoglobin Variants Different types of hemoglobin, with HbA being the most common. Variants can result from genetic mutations.
    Hemoglobin Levels Vary by individual and are measured in grams per deciliter (g/dL). Normal levels range from 12 to 18 g/dL.
    Hemoglobin Disorders Genetic disorders like sickle cell disease and thalassemia are characterized by abnormal hemoglobin production.
    Iron Metabolism Adequate iron levels are essential for hemoglobin synthesis. Iron is a key component of heme in hemoglobin.
    Fetal Hemoglobin Fetal hemoglobin (HbF) has a higher oxygen affinity and aids in oxygen transfer from mother to fetus.
    Hemoglobin Tests Used for diagnosing anemia, assessing health, and monitoring medical conditions.
    Oxygen Saturation Measured as the percentage of hemoglobin molecules bound to oxygen, often using a pulse oximeter.

    New Breakthrough: Haemoglobin Bodies (Hedy)

    • Pathologists in China researching bone development, stumbled upon spherical structures resembling RBCs within chondrocytes.
    • These structures, termed “haemoglobin bodies” or Hedy, contained haemoglobin and formed large, membraneless blobs, akin to phase separation in oil and water.

    Functionality of Hedy

    • Essential for Survival: Experiments on genetically modified mice revealed that chondrocytes without haemoglobin experienced cell death, emphasizing Hedy’s vital role.
    • Oxygen Transport: Similar to RBCs, haemoglobin in chondrocytes likely serves as an oxygen store and supplier, preventing hypoxic stress (low-oxygen conditions) in cartilage cells.

    Haemoglobin’s Broader Implications

    • New Research Avenues: The discovery bridges gaps between haematology and skeletal biology, paving the way for further exploration into the relationship between haemoglobin and stem cell fate in growth plates.
    • Potential for Joint Disease Insights: Functional haemoglobin in cartilage raises possibilities of its involvement in joint diseases and bone deformities, offering fresh insights into disease mechanisms.

    Try this PYQ:

    Excessive release of the pollutant carbon monoxide (CO) into the air may produce a condition in which oxygen supply in the human body decrease. What causes this condition?

    (a) When inhaled into the human body, CO is converted into CO2

    (b) The inhaled CO has much higher affinity for haemoglobin as compared to oxygen

    (c) The inhaled CO destroys the chemical structure of hemoglobin

    (d) The inhaled CO adversely affects the respiratory center in the brain

     

    [wpdiscuz-feedback id=”b2fwk8cvmm” question=”Please leave a feedback on this” opened=”1″]Post your answers here.[/wpdiscuz-feedback]

  • Bats: Extraordinary Creatures and Genomic Secrets

    bats

    Central Idea

    • Bats, by many measures, are truly remarkable organisms.
    • Their lives are notably extended, and they enjoy a unique defense against a range of diseases, including cancer.

    Bats in Numbers

    • Significant Population: Bats constitute a substantial part of the mammal world, making up 20% of all mammal species globally. The planet is home to over 1,400 bat species, each exhibiting its own unique characteristics.
    • Diverse Characteristics: Bats exhibit a wide range of sizes, from the tiny 2-gram bumblebee bat to the formidable flying foxes, boasting a 1.5-meter wingspan and weighing up to 1.6 kg.
    • Ecological Importance: Bats play pivotal roles in maintaining ecological balance by contributing to essential processes such as pollination and insect population control.

    Bats as Virus Reservoirs

    • Notorious Reputation: Bats have come under scrutiny primarily due to their role as hosts for various deadly viruses, including coronaviruses, Nipah, Ebola, Marburg virus, and Hendra virus.
    • COVID-19 Spotlight: The COVID-19 pandemic has thrust bats into the spotlight, raising concerns about their potential impact on human health.
    • Natural Pathogen Hosts: Bats are unique in their ability to harbour numerous pathogens without falling victim to infections, sparking scientific interest in understanding the source of their resistance.

    Unlocking Bat Genomes

    • Genomic Exploration: Scientists have embarked on comprehensive studies of bat genomes, revealing invaluable insights into their distinctive biology.
    • Compact Genomes: Bats boast relatively small genomes, typically consisting of around 2 billion bases, making them ideal subjects for genomic research.
    • Metagenomic Sequencing: The ambitious Bat1K global genome consortium is currently undertaking the task of sequencing genomes of all bat species worldwide, promising further revelations about their genetic makeup.

    Immune Insights from Bat Genomes

    • Crucial Immune Genes: The immune-related genes of bats have been a major focus of research, with these creatures exhibiting unique genomic features.
    • Reduced Immune Genes: Bats possess a smaller percentage of immune-related genes, approximately 2.7-3.5% compared to humans, who have around 7%.
    • Positive Selection: Certain immune genes in bats have undergone positive selection, equipping them to control the spread of viruses while mitigating the inflammatory responses that often prove detrimental to humans.

    Long-Read Sequencing and Deeper Insights

    • Sequencing Advancements: Long-read sequencing technologies have revolutionized our ability to assemble complete genomes quickly and accurately.
    • Immune Response Alterations: Recent research employing long-read technology has revealed significant changes in genes responsible for immune responses in bats.
    • Interferon Dynamics: There has been a shift in the relative proportions of interferon-alpha (IFN-α) and interferon-omega (IFN-ω) in bats, impacting their immune properties.
    • Tumor Suppression and Longevity: Genes linked to tumor suppression and DNA repair in bats exhibit signs of positive selection, contributing to their extended lifespans and reduced cancer risk.

    Future Prospects

    • Emerging Zoonotic Threats: The ongoing processes of deforestation, ecological degradation, and heightened human-animal interactions are anticipated to result in more frequent zoonotic disease outbreaks.
    • Genomic Tools: Advanced genome sequencing techniques hold the promise of aiding in the management of these outbreaks while preserving ecological balance, providing insights without disrupting the delicate equilibrium of nature.

  • How do some Cancer Cells survive Chemotherapy?

    cancer

    Central Idea

    • Researchers at the Netherlands Cancer Institute have conducted a recent study to investigate drug resistance in cancer cells, focusing on resistance to a drug known as Taxol.
    • It studied Chemotherapy and cancer relapse, particularly when a small number of cancer cells resist treatment and remain dormant, potentially leading to a resurgence of the disease.

    Chemotherapy and its limitations

    • Cancer cells are characterized by uncontrolled and rapid division.
    • Chemotherapeutic drugs aim to halt this proliferation, often triggering programmed cell death, known as apoptosis, in response to halted cell division.
    • However, this approach also damages healthy dividing cells, leading to adverse side effects.

    Fine-Tuning Cancer Treatment

    • Oncologists face the challenge of finding an effective drug dose that eliminates cancer cells while minimizing unbearable side effects for patients.
    • One approach has been the development of antibody-drug conjugates (ADCs) that target specific proteins found mainly on cancer cells, sparing non-cancerous cells.

    Unraveling Drug Resistance

    • P-gp Protein: Some cancer cells escape drug treatments by overexpressing a protein called P-gp (permeability glycoprotein), which acts as a pump, expelling toxic compounds, including chemotherapeutic agents.
    • ABCB1 Gene: The production of P-gp is controlled by the ABCB1 gene, and cells that produce excessive P-gp can flush out chemotherapy drugs, preventing them from accumulating at levels needed to trigger apoptosis.

    Role of Cellular Location

    • Recent Findings: The study examined the sensitivity of cells to Taxol and identified that the location of the ABCB1 gene within the cell’s nucleus plays a crucial role.
    • Nuclear Envelope: In sensitive cells, the ABCB1 gene is located close to the nuclear envelope. In resistant cells, the gene has detached from the envelope and moved further inside the nucleus, resulting in a 100-fold increase in ABCB1 gene-related RNA.

    Key Protein: Lamin B Receptor (LBR)

    • LBR’s Influence: Researchers discovered that the presence or absence of a protein called Lamin B Receptor (LBR) affects the location of the ABCB1 gene.
    • Depletion of LBR: When LBR is depleted, cells can activate the ABCB1 gene when exposed to Taxol. However, the absence of the LBR gene itself does not immediately increase ABCB1 expression, indicating the involvement of additional factors.
    • Diverse Responses: Different cancer types exhibit varying responses to LBR depletion, highlighting the complex mechanisms governing gene expression and silencing.
    • Analogy: A simple analogy illustrates the diversity: Different bathrooms offer various options for drying clothes, and cancer cell types rely on different mechanisms to tether genes to the nuclear envelope.

    Significance

    • These findings emphasize the need for further research into the diverse ways cancer cells express or suppress genes.
    • Understanding drug resistance mechanisms opens avenues for developing strategies to maintain the potency of anti-cancer drugs while minimizing side effects, ultimately benefiting patients on their path to recovery.

  • Egypt attains WHO ‘Gold Tier’ status in Hepatitis C Elimination

    Central Idea

    • Egypt has become the first country to achieve the World Health Organization’s “gold tier” status on the path to elimination of Hepatitis C.

    About Hepatitis

    Hepatitis A Hepatitis B Hepatitis C
    Causative Virus Hepatitis A Virus (HAV) Hepatitis B Virus (HBV) Hepatitis C Virus (HCV)
    Transmission Fecal-oral route (contaminated food/water) Blood and body fluids (unsafe sex, sharing needles) Blood-to-blood contact (sharing needles, transfusions)
    Vaccine Available Yes Yes Yes
    Chronic Infection No (usually acute) Yes (can become chronic) Yes (often becomes chronic)
    Symptoms Mild flu-like symptoms, jaundice Variable, from none to severe symptoms Often asymptomatic, but can lead to liver damage
    Chronic Complications None Cirrhosis, liver cancer Cirrhosis, liver cancer
    Preventable by Vaccine Yes Yes No
    Treatment Supportive care Antiviral medications Antiviral medications

     Egypt’s “Gold Tier” Status

    • Stringent Criteria: To reach the “gold tier,” Egypt fulfilled specific criteria, including ensuring 100% blood and injection safety, providing a minimum of 150 needles/syringes annually for people who inject drugs, diagnosing over 80% of individuals with chronic hepatitis C virus (HCV), treating over 70% of diagnosed HCV patients, and establishing a surveillance program for hepatitis sequelae, including liver cancer.
    • Exemplary Results: Egypt has diagnosed 87% of its hepatitis C patients and provided curative treatment to 93% of those diagnosed, surpassing the WHO’s gold tier targets.

    How did Egypt achieve this?

    • “100 Million Healthy Lives” Initiative: Egypt’s ambitious initiative led to a substantial reduction in hepatitis C prevalence, from 10% in 2016 to 5% in 2018 and an estimated less than 1% in 2019, as reported by the Africa CDC.
    • Leadership Role: Egypt extends support to other African countries, aiming to replicate its success in hepatitis C elimination, including enhancing access to affordable treatment.

    Try this PYQ:

    Which one of the following statements is not correct?

    (a) Hepatitis B virus is transmitted much like HIV.

    (b) Hepatitis B, unlike Hepatitis C, does not have a vaccine.

    (c) Globally, the number of people infected with Hepatitis B and C viruses are several times more than those infected with HIV.

    (d) Some of those infected with Hepatitis B and C viruses do not show the symptoms for many years.

     

    [wpdiscuz-feedback id=”q4k2t2jv1z” question=”Please leave a feedback on this” opened=”1″]Post your answers here.[/wpdiscuz-feedback]

  • CAR-T Cell Therapy approved for Cancer

    car-t

    Central Idea

    • The Drug Controller General of India (DCGI) has granted market authorization to CAR-T (Chimeric Antigen Receptor-T) cell therapy, a groundbreaking cancer treatment developed by ImmunoACT, an IIT-Bombay spin-off.
    • This authorization paves the way for its commercial introduction in India.

    About CAR-T Cell Therapy

    What is it?
    • CAR-T cell therapy stands for chimeric antigen receptor T cell therapy.
    • It is a type of cancer immunotherapy that uses the patient’s own T cells, genetically modified in a laboratory to enhance their ability to locate and destroy cancer cells.

    How does it work?
    • T cells are white blood cells responsible for identifying and fighting illness and infection.
    • Each T cell has a receptor that can recognize antigens (proteins or molecules recognized by the immune system).
    • Cancer cells may have antigens that the immune system does not recognize as abnormal, allowing cancer to evade the immune response.
    • CAR-T cells are genetically engineered in the lab to express a new receptor that can bind to cancer cells and effectively kill them.

    Therapy Process

    		 The process involves several steps, including:

    1. Collecting T Cells: Blood is drawn from the patient’s arm, and T cells are separated from the blood using an apheresis machine.

    2. Engineering T Cells: In a laboratory, the T cells are modified by adding a manufactured CAR, and they are allowed to multiply and grow.

    3. Infusing CAR-T Cells: Once enough CAR-T cells are prepared, they are injected back into the patient’s arm.

    • Chemotherapy may be recommended before CAR-T cell infusion to enhance treatment effectiveness.
    • The process can take place in an outpatient infusion center or a hospital setting.

    Cancers Treated
    • CAR-T cell therapy is effective against certain types of cancer, especially when other treatments are ineffective.
    • It is currently FDA-approved for treating haematological malignancies, including leukemia, lymphoma, and multiple myeloma.

  • Diverse Epigenetic Epidemiology Partnership (DEEP)

    Central Idea

    • CSIR-Centre for Cellular and Molecular Biology (CCMB) is spearheading a groundbreaking research endeavour called the “Diverse Epigenetic Epidemiology Partnership (DEEP)”.
    • This integrated genomics and epigenomics study aims to unravel the genetic underpinnings of NCD’s prevalent in diverse populations, including South Asians.

    Diverse Epigenetic Epidemiology Partnership (DEEP)

    • DEEP is an integrated genomics and epigenomics study focused on understanding the genetic factors behind Non-Communicable Diseases (NCDs) in diverse populations, including South Asians.
    • The project spans five years.
    • It aims to uncover the impact of genomic and environmental diversity on disease risk observed in people worldwide, including those in Asia, Africa, North America, and South America.
    • It will study individuals from various genetic and environmental contexts to identify DNA methylation patterns contributing to disease risk in each context.
    • It will develop software, infrastructure, and conduct advanced statistical analyses to create new resources.
    • This will complement international health and genetics databases and examine trends in DNA methylation variation.

    DNA Methylation

    • DNA methylation is a process in which chemical groups attach to DNA, regulating the activation and deactivation of genes.
    • This epigenetic modification helps the body respond to environmental signals and contributes to overall health and disease status.
    • Understanding the relationships between DNA methylation, genetics, and the environment is crucial for comprehending the pathways governing health, disease, and their consequences.

    Significance of this initiative

    • This research will enable the identification of disease-causing mechanisms that are common worldwide and those which are unique to particular groups or regions.
    • It will help with answering questions such as whether medicines developed in one part of the world will be effective for all.
    • Ultimately the DEEP study hopes to enable targeted interventions or treatments and reduce global health disparity and inequity.

  • Advancements in Xenotransplantation

    Xenotransplantation

    Central Idea

    • A groundbreaking study published in Nature showcases a remarkable feat by successfully modifying pig genomes and transplanting kidney grafts from these genetically engineered pigs into non-human primates.
    • This preclinical achievement holds great promise, potentially advancing the prospects of using genetically modified pig kidneys for human transplantation.

    About Xenotransplantation

    • Xenotransplantation Potential: The concept of transplanting animal organs into humans, known as xenotransplantation, offers a potential solution to the chronic shortage of transplantable organs worldwide.
    • Pig Donors Show Promise: Pigs are emerging as promising donor animals. However, several significant hurdles, including organ rejection and the risk of zoonosis (transmission of animal viruses to humans), must be overcome for this approach to be considered clinically viable.

    Recent advances

    • Genome Alterations for Success: Led by Wenning Qin in Cambridge, Massachusetts, the research team took a giant stride by introducing 69 genomic edits into a donor pig, a Yucatan miniature pig.
    • Eliminating Glycan Antigens: Three glycan antigens, culprits for organ rejection, were removed, paving the way for successful transplantation.
    • Human Transgenes Introduced: Seven human transgenes were strategically inserted into the pig’s genome to reduce the primate immune system’s hostility.
    • Porcine Retrovirus Gene Deactivated: The scientists also inactivated all copies of the porcine retrovirus gene.

    Advancement achieved so far

    • Glycan Antigens Identified: Prior research pinpointed three glycan antigens in pigs that trigger rejection when recognized by human antibodies.
    • Zoonotic Concerns: The porcine endogenous retrovirus has raised concerns about the potential transmission of animal viruses to humans during transplantation.
    • Extended Graft Survival: Kidney grafts from genetically engineered pigs exhibited remarkable longevity, far surpassing previous attempts.
    • Enhanced Immunity: Kidney grafts with glycan antigen knockouts and human transgene expression survived significantly longer than those with only glycan antigen knockouts (176 days versus 24 days).
    • Immune Suppression Support: Combining these genetically modified grafts with immunosuppressive treatment resulted in long-term survival for the primate recipients, with survival durations extending up to an impressive 758 days.

    A Step Closer to Clinical Trials

    • Promising Outlook: This groundbreaking research underscores the potential of pig organs for future human transplantation, addressing the organ shortage crisis.
    • Clinical Trials on the Horizon: The successful preclinical study brings the possibility of clinical testing of genetically engineered pig renal grafts within reach, marking a crucial milestone in organ transplantation.

    Issues with Xenotransplantation

    • Animal rights: Many, including animal rights groups, strongly oppose killing animals to harvest their organs for human use.
    • Decreased life expectancy: In the 1960s, many organs came from the chimpanzees, and were transferred into people that were deathly ill, and in turn, did not live much longer afterwards.
    • Religious violations: Certain animals such as pork are strictly forbidden in Islam and many other religions.
    • Informed consent: Autonomy and informed consent are important when considering the future uses of xenotransplantation.
    • Persistent threats of zoonosis: The safety of public health is a factor to be considered. We are already battling the biggest zoonotic disease threat.

  • Uterus Transplants: Procedure, Challenges, and Future Prospects

    Uterus

    Central Idea

    • In the UK, doctors at the Churchill Hospital Oxford conducted the nation’s first uterus transplant.
    • The procedure involved removing a uterus from a 40-year-old woman and transplanting it into her 34-year-old sister, who faced reproductive challenges due to a rare medical condition.

    Why discuss this?

    • While the transplanted womb is functional, its success can only be confirmed by a live birth in the future.

    Understanding Uterus Transplants

    • Not Life-Saving: Unlike heart or liver transplants, uterus transplants are not life-saving procedures. Instead, they are akin to limb or skin transplants, significantly enhancing individuals’ quality of life.
    • Addressing Uterine Infertility: Uterus transplants offer hope to women facing uterine factor infertility, enabling them to fulfill their reproductive aspirations.

    Pioneering Success in Sweden

    • Historical Context: In 2014, Sweden achieved a milestone by witnessing the first live birth following a uterus transplant. This success paved the way for addressing uterine factor infertility.
    • Affordability Challenge: Efforts are ongoing to make uterus transplants more accessible, especially in countries like the UK, where the National Health Service estimates the procedure’s cost at GBP 25,000 (Rs 25.26 lakh).

    Uterus Transplants in India

    • Indian Achievement: India joined the ranks of countries with successful uterus transplants, alongside Turkey, Sweden, and the United States. The country celebrated its first uterine transplant baby’s birth on October 18, 2018, approximately 17 months after the recipient underwent the procedure.
    • Affordable Option: The cost of uterine transplant surgery in India currently ranges from Rs 15-17 lakh, making it a more cost-effective choice for many.

    Step-by-Step Procedure

    • Recipient Evaluation: Before transplantation, recipients undergo thorough evaluations to assess their physical and mental health.
    • Donor Assessment: Whether the donor is living or deceased, their uterus undergoes viability checks before qualifying for donation. Live donors also undergo comprehensive gynecological examinations, including imaging scans and cancer screenings.
    • In Vitro Fertilization (IVF): Uterus transplants do not connect the uterus to the fallopian tubes, necessitating IVF to create embryos. These embryos are then cryopreserved until the transplanted uterus is ready for implantation.
    • Harvesting and Transplantation: The donor’s uterus is carefully removed, with the procedure becoming less invasive due to advancements in robot-assisted laparoscopy. The uterine vasculature and other critical connections are meticulously re-established during transplantation.

    Pregnancy after Transplant

    • The success of the transplant is assessed through three stages: the first three months focus on graft viability, followed by six months to one year for monitoring uterine function.
    • Only after this period can the recipient attempt conception.

    Issues with such transplants

    • Challenges and Risks: Pregnancy after a uterine transplant entails a higher risk of rejection, spontaneous abortion, intrauterine complications, low birth weight, and premature birth. Close monitoring and follow-ups are essential.
    • Immunosuppressant Use: Recipients must take immune-suppressing drugs to prevent rejection of the transplanted uterus. These drugs are selected to ensure they do not harm foetal development but can cause side effects such as kidney toxicity, bone marrow issues, and an increased risk of diabetes and cancer.
    • Long-Term Follow-Ups: Post-uterus removal, recipients are advised to undergo regular follow-ups for at least a decade to monitor potential long-term effects of immunosuppressant drugs.

    Exploring Artificial Uteri

    • Future Possibilities: Successful uterus transplants have opened doors to exploring artificial uteri. These bioengineered organs, grown from stem cells on 3D scaffolds, could eliminate the need for live donors and ethical concerns. However, research is still in its early stages, and it may take about a decade before artificial uteri becomes efficient and safe for human use.
    • Inclusivity Considerations: Artificial uteri could benefit not only women but also members of the LGBTQ+ community. However, certain complications, such as hormone-related considerations for trans-women recipients, remain to be addressed.

    Conclusion

    • Uterus transplants represent a remarkable medical advancement offering hope and possibilities for individuals facing uterine factor infertility.
    • While challenges persist, ongoing research and technological progress continue to expand the horizons of reproductive medicine.